$PCVX SEC Filings

FIRST SUPPLEMENTAL INDENTURE, dated as of October 9, 2026, between Vaxcyte, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), to the Base Indenture (as...

Received 19,000 shares by exercise or conversion ($492K) · Sold 19,000 shares ($1.65M)

Received 18,000 shares by exercise or conversion ($96.3K) · Sold 18,000 shares ($1.56M)

VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21)

Received 2,250 shares by exercise or conversion ($12K) · Sold 2,250 shares ($128K)

Received 52,632 shares as a grant or award · Granted 88,254 Stock Option (right to buy)

Gave up 1,327 shares to cover exercise price or tax ($80.1K)

Gave up 7,651 shares to cover exercise price or tax ($462K)

Sold 1,381 shares ($84.5K) · Gave up 5,459 shares to cover exercise price or tax ($330K) · Sold 1,334 shares ($79.4K)